Abstract
Background: We analyzed prospectively collected data on 145cis-platin hyperthermic isolation limb perfusion (HILPs) for melanoma and soft-tissue sarcoma to determine the pharmacokinetics and maximum tolerable dose ofcis-platin. There were 70 melanoma and 75 sarcoma patients. Dosages ranged from 26 to 265 mg/m2. Perfusate and systemiccis-platin levels were measured in patients perfused at doses of 190–200 mg/m2. Tissue levels were measured in patients perfused at 123–209 mg/m2.
Methods: Cis-platin HILP was well tolerated up to doses of 250 mg/m2 for lower extremities. Higher doses produced toxicities of rhabdomyolysis, myoglobinuria, hyponatremia, and neuropathy. Systemic levels ofcis-platin were equivalent to those of routine intravenous administration, while perfusate levels were 33 times higher. Tissue levels ofcis-platin were five to six times higher than effective intravenous levels.
Results: Six melanoma patients have developed local recurrences. All were perfused at doses <120 mg/m2. However, regional nodal recurrences have occurred in six other patients perfused at doses ≤2000 mg/m2. Four sarcomas have recurred locally, but three of them were present at the time of perfusion.
Conclusions: We conclude that 250 mg/m2 is the maximum tolerable dose ofcis-platin for lower-extremity HILPs. Neoadjuvantcis-platin HILP may improve local control rates for sarcomas. However, no tolerable dose ofcis-platin provides control of nodal metastases from melanoma.
Similar content being viewed by others
References
Creech OJ, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion using an extracorporeal circuit.Am J Surg 1958;148:616–32.
Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities.Surg Gynecol Obstet 1969;129:305–8.
Janoff KA, Moseson D, Nohlgren J, et al. The treatment of stage I melanoma of the extremities by regional hyperthermic isolation perfusion.Ann Surg 1982;196:316–23.
Hartley JW, White CR, Fletcher WS. Improved survival of patients with stage II melanoma of the extremity using hyperthermic isolation perfusion with 1-phenylalanine mustard.J Surg Oncol 1987;36:170–4.
Fletcher JR, White CR, Fletcher WS. Improved survival rates of patients with acral lentiginous melanoma treated with hyperthermic isolation perfusion, wide excision, and regional lymphadenectomy.Am J Surg 1986;151:595–8.
Ghussen F, Nagel K, Groth W, et al. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma.Ann Surg 1984;200:764–8.
Didolkar MS, Fitzpatrick JL, Jackson AJ, Johnston GS. Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DTIC) in melanoma.Cancer 1986;57:1961–6.
Pommier RF, Moseley HS, Cohen J, et al. Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolation limb perfusion for soft-tissue sarcoma and melanoma of the extremities.Am J Surg 1988;155:667–71.
Hajarizadeh H, Mueller C, Woltering EA, et al. Phase I–II trial of hyperthermic isolation limb perfusion with cisplatin in the treatment of high risk malignant melanoma of the extremities.Melanoma Res 1991;1:55–61.
Fletcher WS, Woltering EA, Moseley HS, et al. Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin. In: Humphrey GB, ed.Osteosarcoma in adolescents and young adults. Boston: Kluwer Academic Publishers, 1993;241–4.
Krementz ET, Ryan RF. Chemotherapy of melanoma of the extremities by perfusion: fourteen years clinical experience.Ann Surg 1972;175:900–15.
Wile AG, Nahabedian MY, Pumley DA, et al. Experimental hyperthermic isolation-perfusion using cis-diamminedi-chloroplatinum (II).Cancer Res 1983;43:3108–11.
Kaplan E, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc 1958;53:457–81.
Bielack SS, Erttman R, Looft G, et al. Platinum disposition after intra-arterial and intravenous infusion of cisplatin for osteosarcoma.Cancer Chemother Pharmacol 1989;24:376–80.
Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diamminedichloroplatinum-II (CDP): angiographic, pathologic and pharmacologic studies.Cancer 1983;51:402–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fletcher, W.S., Pommier, R.F., Woltering, E.A. et al. Pharmacokinetics and results of dose escalation inCis-platin hyperthermic isolation limb perfusion. Annals of Surgical Oncology 1, 236–243 (1994). https://doi.org/10.1007/BF02303529
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02303529